Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

28.19 -2.81 (-9.06%)
Official Closing Price Updated: 4:15 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis: 3 Key Takeaways for Long-Term Investors ↗
Ionis's $1.9 billion cash pile buys time, but it is still to be seen whether patient switches to DAWNZERA can offset a slower TRYNGOLZA launch. 
Via The Motley Fool
Topics Earnings
News headline image
Ionis (IONS) Q3 2026 Earnings Call Transcript ↗
Launch ramp slows and cash flow breakeven shifts a year to 2029. 
Via The Motley Fool
Topics Earnings
News headline image
What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call ↗
Ionis Pharmaceuticals (NASDAQ:IONS) lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive... 
Via MarketBeat
Topics Earnings
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
Via Chartmill
News headline image
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating
From Kehoe Law Firm
Via GlobeNewswire
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗
Via Chartmill
News headline image
Ionis reports third quarter 2026 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold third quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis ranked #1 on Science’s Top Employers list
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
This beaten-down biotech has a better story than its stock chart suggests. 
Via The Motley Fool
News headline image
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
The sell-offs for both of these beaten-down biotech stocks appear to be overdone. 
Via The Motley Fool
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool
News headline image
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗
Shares of Ionis are down more than 40% so far this year. 
Via The Motley Fool
News headline image
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while... 
Via MarketBeat
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
Via The Motley Fool
News headline image
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗
Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks. 
Via The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive... 
Via MarketBeat
News headline image
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
Via The Motley Fool
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
News headline image
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.